A Cross-Reactivity of Fenofibric Acid With MDMA DRI Assay.
Mil Med
; 181(9): 1013-5, 2016 09.
Article
en En
| MEDLINE
| ID: mdl-27612346
ABSTRACT
BACKGROUND:
Within the framework of routine fitness examinations, French Air Force military crew underwent urine testing for 3,4 methylenedioxymetamphetamine (MDMA [ecstasy]). The cross-reactivity of a dyslipidemic drug, fenofibrate, with an MDMA immunoassay was studied and confirmed on a large population sample.METHODS:
A 3-year retrospective study was performed on the MDMA DRI Ecstasy Assay on the Unicel DXC 600. In the event of positive test result, a confirmatory testing was carried out by gas chromatography/mass spectrometry (GC/MS) to establish the presence of MDMA. When analysis by GC/MS did not confirm the presence of MDMA, a false-positive result was suspected and the samples were analyzed by high-performance liquid chromatography-mass spectrometry to identify a potential interfering substance.RESULTS:
A total of 15,169 urine samples, from 7,803 patients, were tested for 3 years. Of the tested samples, 22 (0.15%) were positive by DRI Ecstasy Assay. None of them were positive by GC/MS. A cross-reactivity of fenofibrate's metabolite with MDMA using this assay was systematically found.CONCLUSION:
Fenofibrate's interference with MDMA immunoassay was confirmed. Fenofibrate being widely prescribed, physicians had to be alerted that this treatment could lead to false-positive results.
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Fenofibrato
/
N-Metil-3,4-metilenodioxianfetamina
/
Evaluación Preclínica de Medicamentos
/
Reacciones Falso Positivas
Tipo de estudio:
Observational_studies
/
Prognostic_studies
País/Región como asunto:
Europa
Idioma:
En
Revista:
Mil Med
Año:
2016
Tipo del documento:
Article
País de afiliación:
Francia